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median age of patients was 4.8 years old (range 2–11 years) with a
median weight of 17.5 kg (range 12–38 kg). The primary data was
audited by one of the authors at a different institution (J.R.). With
12 cord blood units for 10 patients (2 double unit CBT), there were
three 6/6, three 5/6, two 4/6, and four 3/6 high resolution HLA
A/B/DR matches. To maximize cell dose, all UCB units were
depleted of plasma but not of red blood cell (RBC), and were
thawed and infused immediately without washing. No signiﬁcant
adverse events were observed after infusion despite major ABO
incompatibility in most cases. Median pre-freeze total nucleated
cell dose was 8.7  107/kg (range 4.8–15.0  107/kg), and median
pre-freeze CD34 cell dose was 4.1  105/kg (range 2.1–8.0 
105/kg) of the recipient’s body weight. One patient died of peni-
cillin-resistant S. mitis sepsis at day 8 unrelated to the CBU. All
remaining 9 patients are alive and thalassemia free with a median
follow-up time of 378 days (range 82–713 days) as of October 8,
2005. Eight patients with neutrophil engraftment showed full do-
nor chimerism by day 21 and the remaining patient achieved
stable mixed chimerism (85.6% donor’s cells) by day 162 and is
currently at day 311 post-transplant. Autologous recovery was not
seen in any of the patients. The median times to ANC 500 en-
graftment, RBC transfusion independence, and platelet 20 K en-
graftment were 14 (range 12–4 days), 35 (range 20–50 days), and
51 (range 45–60 days) days after transplantation, respectively. All
surviving patients experienced grade I-II acute GvHD that re-
solved with treatment, with no extensive chronic GvHD. The
median day to hospital discharge was day 78 (range 46–98 days).
These results show that when cell dose is optimal, unrelated CBT
may be a promising approach for the curative therapy of thalasse-
mia major.
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Background: Allogeneic transplant results in the best outcomes
for pediatric patients with myeloid malignancies and matched sib-
ling donors (MRD). Improvements in supportive care, prophylaxis
of infections, and treatment of GvHD has decreased non-relapse
related morbidity and mortality. Conditioning regimens without
TBI would be expected to result in less long term toxicity, but may
not be as effective in preventing relapse. We report results of
allogeneic MRD transplantation after a busulfan (Bu) and melpha-
lan (Mel) conditioning regimen for a group of 36 pediatric patients
transplanted at a single center. Methods: From 11/93–9/05, 36
children with AML or MDS received Bu (1 mg/kg/dose  16
doses) and Mel (60 mg/m2 daily 3) followed by a 5/6 or 6/6 HLA
MRD BMT. GvHD prophylaxis was CyA and MTX. Twenty-nine
patients had AML: 19 in CR1; 3 in CR2; 7 were either induction
failures or were in relapse at the time of transplant. Seven patients
had MDS: 5 were de novo patients; 1 was a patient constitutionally
mosaic for trisomy 8, and 1 was a patient with monosomy 7
following treatment for ALL. Patients were evaluated for engraft-
ment, toxicity, relapse, and overall survival. Results: All donors
were siblings, either HLA identical (n  34) or a 5/6 match caused
by a crossover event (n  2). All patients successfully engrafted
with a median time to engraftment (ANC 	 500/uL) of 14 days.
Five patients experienced grade II acute graft-versus-host disease
(aGvHD) and 3 experienced chronic GvHD (1 limited and 2
extensive). No patient died of infection, 1 died of pulmonary
toxicity, 1 patient survived an intracranial hemorrhage with neu-
rological sequela, and 1 patient survived a diffuse pulmonary alve-
olar hemorrhage. Seven AML patients relapsed (6 in marrow and
one isolated CNS chloroma) yielding a 75% disease free survival
and an 80% overall survival. All of the marrow relapsed patients
subsequently died (4 were CR1 and 2 were in relapse at the time of
BMT). All 7 MDS patients survive disease free. With a median
follow-up of 6 years the disease free and overall survival are both
29/36 (81%). Non-relapse mortality was 1 out of 36 (3%). Con-
clusions: Bu/Mel is an effective, well tolerated conditioning reg-
imen for pediatric patients with AML or MDS. Leukemic relapse,
occurring in 25% of the AML patients, remains the main cause of
treatment failure. Additional trials are indicated to verify these
results at other pediatric transplant centers.
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UNRELATED DONOR LYMPHOCYTE INFUSIONS AS A TREATMENT OF
IMMUNODEFICIENCY IN COMPLETE DI GEORGE SYNDROME
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Complete DiGeorge syndrome (DGS) is a rare congenital dis-
order characterized by number of developmental defects and T-
cell deﬁciency. We present an infant with multiple anomalies
(choanal and esophageal atresia, coloboma, tracheobronchomala-
cia, etc.), diagnosed at the age of 2 months with complete DGS
(absence of T cells, no response to mitogens, absent thymus),
treated with unrelated donor lymphocyte infusion (DLI). During
ﬁrst 7 months of age he required long-term ventilation, suffered
recurrent infections, and sepsis. He had no sibling and no fully
matched unrelated donor was available. At the age of 6 months the
ﬁrst dose of DLI (1  106 /kg CD3; 2 105/kg CD34) was
administered to him from an unrelated donor (mismatched for B
and Cw alleles) with no conditioning regimen and no graft versus
host disease (GVHD) prophylaxis. Ten days after DLI, he devel-
oped severe acute GVHD (skin stage 3–4) complicated with sepsis,
cardiopulmonary instability, capillary leak syndrome, and ileus. He
was treated with antithymocyte globulin (rATG), cyclosporin A
(CsA), and steroids with a complete resolution of GVHD. On day
36 after ﬁrst DL, he was given the second DLI (0.9  106/kg
CD3) with no conditioning and GVHD prophylaxis consisting
of continued CsA. EBV infection has appeared 4 weeks after
infusion (peripheral expansion of CD8 donor cells started), suc-
cessfully treated with CsA withdrawal and rituximab. Isolated cho-
lestatic liver GVHD manifested month after second DLI, pro-
gressed to stage 4, successfully treated with steroids, CsA, and
rATG. Since day 10 after ﬁrst DLI, the donor genotype due to
presence of donor T cells is documented in VNTR. Response to
mitogens appeared and is now comparable to healthy controls.
Central memory (CD27pos, CD45RAneg) stages dominate in the
peripheral blood CD4 and CD8 cells (64 to 81% and 52 to 95%,
respectively), which was higher than in control. Effector memory
cells are increased in CD4 subset, decreased in CD8. Naive CD4
T cells (CD45RApos, CD27pos) continued to be completely absent
at all time-point measured, but naive CD8 (CD45RApos, CD27pos)
were detected already at D 100 at 5% and continued raise
thereafter. The patient is now 10 months after ﬁrst DLI still on
CsA and steroids, slowly started to gain his developmental mile-
stones. We believe that infusions of small doses of DLI from an
unrelated donor represent an adequate therapy for complete Di-
George syndrome. Supported by NI 7410-3, MSM0021620812.
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS WITH WISKOTT
ALDRICH SYNDROME (WAS): ANALYSIS OF 19 PTS TRANSPLANTED IN
BRAZIL AND CHILE
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Funke, V.1, Koliski, A.3, Bitencourt, M.1, Pasquini, R.1 1. Federal
University of Parana, Curitiba, PR, Brazil; 2. Pontiﬁcia Universidad
Catolica, Santiago, Chile; 3. Pediatric Intensive Care Unit, Curitiba,
PR, Brazil.
WAS is a rare X linked disorder characterized by eczema, throm-
bocytopenia with small platelets, and increased susceptibility to
infections autoimmune diseases and malignancies. SCT from
matched related or unrelated donors is considered the treatment of
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